399 related articles for article (PubMed ID: 20211987)
1. Regulation of ERRalpha gene expression by estrogen receptor agonists and antagonists in SKBR3 breast cancer cells: differential molecular mechanisms mediated by g protein-coupled receptor GPR30/GPER-1.
Li Y; Birnbaumer L; Teng CT
Mol Endocrinol; 2010 May; 24(5):969-80. PubMed ID: 20211987
[TBL] [Abstract][Full Text] [Related]
2. Estrogen induces estrogen-related receptor alpha gene expression and chromatin structural changes in estrogen receptor (ER)-positive and ER-negative breast cancer cells.
Hu P; Kinyamu HK; Wang L; Martin J; Archer TK; Teng C
J Biol Chem; 2008 Mar; 283(11):6752-63. PubMed ID: 18174157
[TBL] [Abstract][Full Text] [Related]
3. G protein-coupled receptor 30 (GPR30) mediates gene expression changes and growth response to 17beta-estradiol and selective GPR30 ligand G-1 in ovarian cancer cells.
Albanito L; Madeo A; Lappano R; Vivacqua A; Rago V; Carpino A; Oprea TI; Prossnitz ER; Musti AM; Andò S; Maggiolini M
Cancer Res; 2007 Feb; 67(4):1859-66. PubMed ID: 17308128
[TBL] [Abstract][Full Text] [Related]
4. GPER mediates the Egr-1 expression induced by 17β-estradiol and 4-hydroxitamoxifen in breast and endometrial cancer cells.
Vivacqua A; Romeo E; De Marco P; De Francesco EM; Abonante S; Maggiolini M
Breast Cancer Res Treat; 2012 Jun; 133(3):1025-35. PubMed ID: 22147081
[TBL] [Abstract][Full Text] [Related]
5. The G protein-coupled receptor GPR30 inhibits proliferation of estrogen receptor-positive breast cancer cells.
Ariazi EA; Brailoiu E; Yerrum S; Shupp HA; Slifker MJ; Cunliffe HE; Black MA; Donato AL; Arterburn JB; Oprea TI; Prossnitz ER; Dun NJ; Jordan VC
Cancer Res; 2010 Feb; 70(3):1184-94. PubMed ID: 20086172
[TBL] [Abstract][Full Text] [Related]
6. MIBE acts as antagonist ligand of both estrogen receptor α and GPER in breast cancer cells.
Lappano R; Santolla MF; Pupo M; Sinicropi MS; Caruso A; Rosano C; Maggiolini M
Breast Cancer Res; 2012 Jan; 14(1):R12. PubMed ID: 22251451
[TBL] [Abstract][Full Text] [Related]
7. Estrogen action via the G protein-coupled receptor, GPR30: stimulation of adenylyl cyclase and cAMP-mediated attenuation of the epidermal growth factor receptor-to-MAPK signaling axis.
Filardo EJ; Quinn JA; Frackelton AR; Bland KI
Mol Endocrinol; 2002 Jan; 16(1):70-84. PubMed ID: 11773440
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen regulation of bone growth and endocrine function in the ovariectomized rat: discrimination of responses involving estrogen receptor α/estrogen receptor β, G protein-coupled estrogen receptor, or estrogen-related receptor γ using fulvestrant (ICI 182780).
Fitts JM; Klein RM; Powers CA
J Pharmacol Exp Ther; 2011 Jul; 338(1):246-54. PubMed ID: 21464335
[TBL] [Abstract][Full Text] [Related]
9. Tamoxifen and ICI 182,780 activate hypothalamic G protein-coupled estrogen receptor 1 to rapidly facilitate lordosis in female rats.
Long N; Long B; Mana A; Le D; Nguyen L; Chokr S; Sinchak K
Horm Behav; 2017 Mar; 89():98-103. PubMed ID: 28063803
[TBL] [Abstract][Full Text] [Related]
10. Two novel GPER agonists induce gene expression changes and growth effects in cancer cells.
Lappano R; Rosano C; Santolla MF; Pupo M; De Francesco EM; De Marco P; Ponassi M; Spallarossa A; Ranise A; Maggiolini M
Curr Cancer Drug Targets; 2012 Jun; 12(5):531-42. PubMed ID: 22414008
[TBL] [Abstract][Full Text] [Related]
11. The G protein-coupled receptor GPR30 mediates the proliferative effects induced by 17beta-estradiol and hydroxytamoxifen in endometrial cancer cells.
Vivacqua A; Bonofiglio D; Recchia AG; Musti AM; Picard D; Andò S; Maggiolini M
Mol Endocrinol; 2006 Mar; 20(3):631-46. PubMed ID: 16239258
[TBL] [Abstract][Full Text] [Related]
12. Disruption of 3D MCF-12A breast cell cultures by estrogens--an in vitro model for ER-mediated changes indicative of hormonal carcinogenesis.
Marchese S; Silva E
PLoS One; 2012; 7(10):e45767. PubMed ID: 23056216
[TBL] [Abstract][Full Text] [Related]
13. Enhanced expression of G-protein coupled estrogen receptor (GPER/GPR30) in lung cancer.
Jala VR; Radde BN; Haribabu B; Klinge CM
BMC Cancer; 2012 Dec; 12():624. PubMed ID: 23273253
[TBL] [Abstract][Full Text] [Related]
14. Interplay of estrogen receptors and GPR30 for the regulation of early membrane initiated transcriptional effects: A pharmacological approach.
Notas G; Kampa M; Pelekanou V; Castanas E
Steroids; 2012 Aug; 77(10):943-50. PubMed ID: 22138208
[TBL] [Abstract][Full Text] [Related]
15. Cooperative activation of gene expression by agonists and antagonists mediated by estrogen receptor heteroligand dimer complexes.
Liu S; Han SJ; Smith CL
Mol Pharmacol; 2013 May; 83(5):1066-77. PubMed ID: 23462505
[TBL] [Abstract][Full Text] [Related]
16. The G protein-coupled receptor GPR30 mediates c-fos up-regulation by 17beta-estradiol and phytoestrogens in breast cancer cells.
Maggiolini M; Vivacqua A; Fasanella G; Recchia AG; Sisci D; Pezzi V; Montanaro D; Musti AM; Picard D; Andò S
J Biol Chem; 2004 Jun; 279(26):27008-16. PubMed ID: 15090535
[TBL] [Abstract][Full Text] [Related]
17. Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF.
Filardo EJ; Quinn JA; Bland KI; Frackelton AR
Mol Endocrinol; 2000 Oct; 14(10):1649-60. PubMed ID: 11043579
[TBL] [Abstract][Full Text] [Related]
18. Insulinotropic and antidiabetic effects of 17β-estradiol and the GPR30 agonist G-1 on human pancreatic islets.
Kumar R; Balhuizen A; Amisten S; Lundquist I; Salehi A
Endocrinology; 2011 Jul; 152(7):2568-79. PubMed ID: 21521748
[TBL] [Abstract][Full Text] [Related]
19. Characterization of a novel small molecule subtype specific estrogen-related receptor alpha antagonist in MCF-7 breast cancer cells.
Chisamore MJ; Cunningham ME; Flores O; Wilkinson HA; Chen JD
PLoS One; 2009 May; 4(5):e5624. PubMed ID: 19462000
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of GPR30 reduces growth of triple-negative breast cancer cells: possible application in targeted therapy.
Girgert R; Emons G; Gründker C
Breast Cancer Res Treat; 2012 Jul; 134(1):199-205. PubMed ID: 22290080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
